SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Oscar Health, Inc. – ‘8-K’ for 11/8/22

On:  Tuesday, 11/8/22, at 4:21pm ET   ·   For:  11/8/22   ·   Accession #:  1568651-22-54   ·   File #:  1-40154

Previous ‘8-K’:  ‘8-K’ on / for 9/8/22   ·   Next:  ‘8-K’ on 12/7/22 for 12/6/22   ·   Latest:  ‘8-K’ on / for 5/7/24   ·   1 Reference:  To:  Oscar Health, Inc. – ‘DEF 14A’ on 4/26/22 for 6/9/22

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

11/08/22  Oscar Health, Inc.                8-K:2,5,7,911/08/22   12:2.5M

Current Report   —   Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     44K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML    456K 
 3: EX-99.2     Miscellaneous Exhibit                               HTML     20K 
 7: R1          Cover Page                                          HTML     45K 
10: XML         IDEA XML File -- Filing Summary                      XML     12K 
 8: XML         XBRL Instance -- oscr-20221108_htm                   XML     21K 
 9: EXCEL       IDEA Workbook of Financial Reports                  XLSX      8K 
 5: EX-101.LAB  XBRL Labels -- oscr-20221108_lab                     XML     67K 
 6: EX-101.PRE  XBRL Presentations -- oscr-20221108_pre              XML     33K 
 4: EX-101.SCH  XBRL Schema -- oscr-20221108                         XSD     10K 
11: JSON        XBRL Instance as JSON Data -- MetaLinks               11±    17K 
12: ZIP         XBRL Zipped Folder -- 0001568651-22-000054-xbrl      Zip     60K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX:   C:  C: 
  oscr-20221108  
 i 0001568651 i FALSE00015686512022-11-082022-11-08

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM  i 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):  i November 8, 2022
 i Oscar Health, Inc.
(Exact Name of Registrant as Specified in its Charter)
 i Delaware i 001-40154 i 46-1315570
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)

 i 75 Varick Street, 5th Floor
 i New York,  i New York  i 10013
(Address of Principal Executive Offices) (Zip Code)
( i 646)  i 403-3677
(Registrant’s telephone number, including area code)
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 i Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
 i Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
 i Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
 i Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbols
Name of each exchange
on which registered
 i Class A Common Stock, $0.00001 par value per share i OSCR i New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  i 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 2.02. Results of Operations and Financial Condition.
On November 8, 2022, Oscar Health, Inc. (the “Company”), announced the Company’s financial results for the quarter ended September 30, 2022. A copy of the press release issued in connection with the announcement is attached and furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 7, 2022, the Board of Directors of the Company (the “Board”) appointed R. Scott Blackley as the Chief Transformation Officer of the Company and Siddhartha Sankaran as Interim Chief Financial Officer of the Company, each effective December 1, 2022 (the “Transition Date”).

In the role of Chief Transformation Officer, Mr. Blackley will focus on managing the alignment of our overall revenues with our costs for both InsuranceCo and total Company profitability and will oversee the Company’s operations, +Oscar business and corporate strategy. Mr. Sankaran, the Company’s former Chief Financial Officer and current chair of the Finance, Risk & Investment Committee (the “FR&I Committee”) of the Board, will lead treasury, actuarial, financial reporting, capital management and investor relations. Mr. Sankaran will serve as the Company’s principal financial officer while acting in the capacity of Interim Chief Financial Officer, and Mr. Blackley will serve as the Company’s principal operating officer while acting in the capacity of Chief Transformation Officer.

In connection with the transition, the Company has amended Mr. Blackley’s Employment Agreement with the Company (the “Employment Agreement Amendment”). The Employment Agreement Amendment does not make any change to Mr. Blackley’s base salary or equity compensation, but removes the partial equity acceleration that otherwise would have become due upon Mr. Blackley’s non-change in control qualifying termination. Furthermore, in connection with certain terminations of employment, the Employment Agreement Amendment provides that the Company and Mr. Blackley will enter into a two-year consulting arrangement, during which all outstanding Company equity awards then held by Mr. Blackley will remain outstanding and eligible to vest and, as applicable, become exercisable, in accordance with their respective terms and conditions.

Siddhartha Sankaran, age 45, has served (and, following the transition, will continue to serve) as a member of the Board since February 2021 and previously served as the Company’s Chief Financial Officer from March 2019 to March 2021. Mr. Sankaran also provided transitional services to the Company from March 2021 to June 2021. Mr. Sankaran is the former Chairman and Chief Executive Officer of SiriusPoint Ltd., a global (re)insurance company, and previously served as chairman and a member of the board of directors of Third Point Reinsurance Ltd., the predecessor to SiriusPoint. Mr. Sankaran has had a number of other executive roles in the insurance industry, including serving as Executive Vice President and Chief Financial Officer of American International Group, Inc. (“AIG”), a global insurance company, from February 2016 to December 2018. Prior to that, he served as Executive Vice President and Chief Risk Officer at AIG from November 2010 to February 2016. Previously he was a Partner at Oliver Wyman, a global management consultancy. Mr. Sankaran holds a Bachelor of Mathematics degree, majoring in actuarial science, with distinction from the University of Waterloo.

In connection with his appointment, Mr. Sankaran and the Company have entered into a letter agreement (the “Offer Letter”). Under the Offer Letter, Mr. Sankaran will commence employment with the Company on November 9, 2022, and on the Transition Date he will become the Interim Chief Financial Officer of the Company. While Mr. Sankaran is employed by the Company, he will not serve as a member of the FR&I Committee.

In addition, Mr. Sankaran has been granted an award of restricted stock units with an aggregate value of $3,600,000 (the “RSU Award”) under the Company’s 2021 Incentive Award Plan. The RSU Award will vest with respect to 1/4 of the restricted stock units underlying the RSU Award on each of the first four quarterly anniversaries of the Transition Date, subject to Mr. Sankaran’s continued employment through the applicable vesting date.

During his term as Interim Chief Financial Officer, Mr. Sankaran will not be eligible to receive an annual base salary or annual target bonus opportunity under his Offer Letter.



Biographical information for Mr. Blackley, age 54, was included on page 20 of the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 26, 2022, and is incorporated by reference herein.
Item 7.01. Regulation FD Disclosure.
On November 8, 2022, the Company posted an earnings presentation in the “Investor Relations” portion of its website at ir.hioscar.com. A copy of the earnings presentation is attached and furnished as Exhibit 99.2 to this Current Report on Form 8-K.
The information in Items 2.02 and 7.01 and Exhibits 99.1 and 99.2 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information and exhibits be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.Description
99.1
99.2
104Cover Page Interactive Data File (embedded within the Inline XBRL document).



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Oscar Health, Inc.
By:/s/ R. Scott Blackley
Name:R. Scott Blackley
Title:Chief Financial Officer
Date: November 8, 2022


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
12/1/22
11/9/22
Filed on / For Period end:11/8/22
11/7/22SC 13G/A
9/30/22
4/26/22DEF 14A,  DEFA14A
 List all Filings 


1 Previous Filing that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/26/22  Oscar Health, Inc.                DEF 14A     6/09/22    1:2M                                     Donnelley … Solutions/FA
Top
Filing Submission 0001568651-22-000054   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., May 16, 6:28:45.2am ET